## Iver Nordentoft

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9506191/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circulating tumor <scp>DNA</scp> for prognosis assessment and postoperative management after curativeâ€intent resection of colorectal liver metastases. International Journal of Cancer, 2022, 150, 1537-1548.	5.1	22
2	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301.	12.8	159
3	Genome-wide circulating tumor DNA monitoring for bladder cancer treatment management and organ preservation Journal of Clinical Oncology, 2021, 39, e16527-e16527.	1.6	0
4	SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer. European Urology Open Science, 2021, 34, 59-67.	0.4	1
5	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	27.8	221
6	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nature Communications, 2020, 11, 4858.	12.8	124
7	Epigenetic and transcriptomic consequences of excess Xâ€chromosome material in 47, <scp>XXX</scp> syndrome—A comparison with Turner syndrome and 46, <scp>XX</scp> females. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 279-293.	1.6	21
8	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
9	Mutational Analysis of Field Cancerization in Bladder Cancer. Bladder Cancer, 2020, 6, 253-264.	0.4	12
10	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology, 2019, 5, 1124.	7.1	538
11	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology, 2019, 37, 1547-1557.	1.6	298
12	Abstract 913: Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. , 2019, , .		3
13	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific Reports, 2018, 8, 1917.	3.3	50
14	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. European Urology, 2018, 73, 535-540.	1.9	112
15	Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patientâ€derived spheroid cultures. Molecular Oncology, 2018, 12, 132-147.	4.6	49
16	Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. Modern Pathology, 2018, 31, 1869-1881.	5.5	47
17	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 2017, 71, 961-969.	1.9	154
18	Altered gene expression and repressed markers of autophagy in skeletal muscle of insulin resistant patients with type 2 diabetes. Scientific Reports, 2017, 7, 43775.	3.3	57

**IVER NORDENTOFT** 

#	Article	IF	CITATIONS
19	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clinical Cancer Research, 2017, 23, 5437-5445.	7.0	232
20	Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Scientific Reports, 2017, 7, 395.	3.3	117
21	Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Scientific Reports, 2017, 7, 11702.	3.3	110
22	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget, 2017, 8, 5774-5788.	1.8	22
23	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Research, 2016, 76, 5894-5906.	0.9	87
24	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Molecular Oncology, 2016, 10, 1450-1460.	4.6	44
25	Widespread DNA hypomethylation and differential gene expression in Turner syndrome. Scientific Reports, 2016, 6, 34220.	3.3	106
26	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell, 2016, 30, 27-42.	16.8	486
27	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut, 2016, 65, 625-634.	12.1	381
28	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. European Urology, 2016, 70, 75-82.	1.9	174
29	Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue. PLoS ONE, 2014, 9, e98187.	2.5	284
30	Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. Cancer Research, 2014, 74, 5758-5771.	0.9	237
31	Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer. Cell Reports, 2014, 7, 1649-1663.	6.4	128
32	miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Medical Genomics, 2012, 5, 40.	1.5	86
33	Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer. BMC Cancer, 2011, 11, 135.	2.6	35
34	Expression Analysis of cPLA2 Alpha Interacting TIP60 in Diabetic KKAy and Non-Diabetic C57BL Wild-Type Mice: No Impact of Transient and Stable TIP60 Overexpression on Glucose-Stimulated Insulin Secretion in Pancreatic Beta-Cells. Review of Diabetic Studies, 2007, 4, 147-158.	1.3	0